Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genmab | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 91.21B | 81x | 0.05 | DKK 1,481 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
Zealand Pharma | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 32.04B | -24.8x | 0.74 | DKK 451.40 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gubra AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 8.85B | -228.7x | -10.39 | DKK 543 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36% Upside | Upgrade to Pro+ | |
ViroGates | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 71.16M | -3.8x | -0.46 | DKK 9.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Strategic Partners AS | Copenhagen | Healthcare | Biotechnology & Medical Research | DKK 41.29M | -112.2x | -1.4 | DKK 990 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |